Request Demo
Last update 20 Mar 2025
SAL-023
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Romosozumab-AQQG Biosimilar (Shenzhen Salubris Pharmaceuticals Co., Ltd.) |
Target |
Action inhibitors |
Mechanism SOST inhibitors(Sclerostin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 51543H
The sequence is quoted from: *****
Sequence Code 51535L
The sequence is quoted from: *****
Related
1
Clinical Trials associated with SAL-023CTR20244935
在中国健康成年男性受试者中初步比较 SAL023 和 Evenity的药代动力学、药效动力学、安全性和免疫原性的随机、开放、单次给药、平行对照的生物类似药比对研究
[Translation] A randomized, open-label, single-dose, parallel-controlled biosimilar comparison study to preliminarily compare the pharmacokinetics, pharmacodynamics, safety and immunogenicity of SAL023 and Evenity in healthy adult male subjects in China
100 Clinical Results associated with SAL-023
Login to view more data
100 Translational Medicine associated with SAL-023
Login to view more data
100 Patents (Medical) associated with SAL-023
Login to view more data
100 Deals associated with SAL-023
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis | Phase 1 | China | 27 Dec 2024 | |
| Osteoporosis, Postmenopausal | IND Approval | China | 18 Sep 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free